Development of fluorine-18-labeled 5-HT1A antagonists

被引:101
作者
Lang, LX
Jagoda, E
Schmall, B
Vuong, BK
Adams, HR
Nelson, DL
Carson, RE
Eckelman, WC
机构
[1] NIH, Ctr Clin, Positron Emiss Tomog Dept, Bethesda, MD 20892 USA
[2] Eli Lilly & Co, Indianapolis, IN 46285 USA
关键词
D O I
10.1021/jm980456f
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
We have synthesized five fluorinated derivatives of WAY 100635, N-{2-[4-(2-methoxyphenyl)piperazino]ethyl)-N-(2-pyridyl)cyclohexanecarboxamide (4a), using various acids in place of the cyclohexanecarboxylic acid (CHCA, 2a) in the reaction scheme. The five acids are 4-fluorobenzoic acid (FB, 2b), 4-fluoro-3-methylbenzoic acid (MeFB, 2c), trans-4-fluorocyclohexanecarboxylic acid (FC, 2d), 4-(fluoromethyl)benzoic acid (FMeB, 2e), and 3-nitro-4-(fluoromethyl)benzoic acid (NFMeB, 2f) (see Scheme 1). These compounds were radiolabeled with fluorine-18, and their biological properties were evaluated in rats and compared with those of [C-11]carbonyl WAY 100635 ([carbonyl-C-11]4a), [Carbonyl-C-11]4a cleared the brain with a biological half-life averaging 41 min. The metabolite-corrected blood radioactivity had a half-life of 29 min. [F-18]FCWAY ([F-18]4d) gave half-lives and intercepts comparable to [carbonyl-C-11]4a in the brain, but the blood clearance was faster. [F-18]FBWAY ([F-18]4b) showed an early rapid net efflux from the whole brain, clearing with a biological half-life of 35 min. The metabolite-corrected blood half-life was 41 min. The comparable whole brain and blood half-lives for Me[F-18]FBWAY ([F-18]4c) were 16 and 18 min, respectively. For each compound, the corresponding carboxylic acid was identified as a major metabolite in blood. Fluoride was also found after injection of [F-18]4d. However, for all compounds there was a good correlation (R > 0.97) between the differential uptake ratio (DUR, (%ID/g) x body weight (g)/100) in individual rat brain regions at 30 min after injection and the concentration of receptors as determined by in vitro quantitative autoradiography in rat. Specific binding ratios [region of interest (ROI)/ cerebellum-1] in control studies for cortex (Ctx) and hippocampus (H) were higher for [carbonyl-C-11]4a and [F-18]4d compared to [F-18]4b and [F-18]4c. [F-18]4d has similar pharmacokinetic properties and comparable specific binding ratios to [carbonyl-11C]4a. Fifty nanomoles of 4a blocked only 30% of the specific binding of [F-18]4d, while complete blockade was obtained from co-injection of 200 nmol of 4a (H/Cb-1 from 17.2 to 0.6). [F-18]4b and [F-18]4c showed lower specific binding ratios than [carbonyl-C-11]4a and [F-18]4d. [F-18]4c was superior to [F-18]4b since its specific binding was more readily blocked by 4a. These studies suggest that [F-18]4c should be a useful compound to assess dynamic changes in serotonin levels while [F-18]4d, with its high contrast and F-18 label, should provide better statistics and quantification for static measurement of 5-HT1A receptor distribution.
引用
收藏
页码:1576 / 1586
页数:11
相关论文
共 31 条
[1]  
ALEXANDER SPH, 1998, TIPS
[2]   METABOLISM OF CYCLOHEXANECARBOXYLATE IN RAT [J].
BREWSTER, D ;
JONES, RS ;
PARKE, DV .
BIOCHEMICAL JOURNAL, 1977, 164 (03) :595-&
[3]   CARCINOGENIC NITROGEN COMPOUNDS .12. FLUORINE-CONTAINING 1-2- AND 3-4-BENZACRIDINES [J].
BUUHOI, NP ;
JACQUIGNON, P .
JOURNAL OF THE CHEMICAL SOCIETY, 1952, (NOV) :4173-4175
[4]  
CARSON R, 1997, J CEREB BLOOD FLOW S, V17, pS327
[5]  
Carson R. E., 1997, Journal of Nuclear Medicine, V38, p80P
[6]   LIGANDS AND TRACERS FOR PET STUDIES OF THE 5-HT SYSTEM - CURRENT STATUS [J].
CROUZEL, C ;
GUILLAUME, M ;
BARRE, L ;
LEMAIRE, C ;
PIKE, VW .
NUCLEAR MEDICINE AND BIOLOGY, 1992, 19 (08) :857-870
[7]   INVIVO COMPETITION STUDIES WITH ANALOGS OF 3-QUINUCLIDINYL BENZILATE [J].
ECKELMAN, WC ;
GRISSOM, M ;
CONKLIN, J ;
RZESZOTARSKI, WJ ;
GIBSON, RE ;
FRANCIS, BE ;
JAGODA, EM ;
ENG, R ;
REBA, RC .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1984, 73 (04) :529-534
[8]   WAY100135 - A NOVEL, SELECTIVE ANTAGONIST AT PRESYNAPTIC AND POSTSYNAPTIC 5-HT(1A) RECEPTORS [J].
FLETCHER, A ;
BILL, DJ ;
BILL, SJ ;
CLIFFE, IA ;
DOVER, GM ;
FORSTER, EA ;
HASKINS, JT ;
JONES, D ;
MANSELL, HL ;
REILLY, Y .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1993, 237 (2-3) :283-291
[9]  
FLETCHER A, 1993, TIPS, V141, P441
[10]   A PHARMACOLOGICAL PROFILE OF THE SELECTIVE SILENT 5-HT1A RECEPTOR ANTAGONIST, WAY-100635 [J].
FORSTER, EA ;
CLIFFE, IA ;
BILL, DJ ;
DOVER, GM ;
JONES, D ;
REILLY, Y ;
FLETCHER, A .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1995, 281 (01) :81-88